Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00457119 · ClinicalTrials.gov registry record · Phase 1

Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients

A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
69
Enrollment target
8
Study locations

NCT00457119 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 69 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00457119, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
69 participants
Enrollment target
8
Study locations

Study Summary

This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD 001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in combination with carboplatin, paclitaxel and bevacizumab

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG RAD001

Study Locations (8)

Texas

  • U of TX Southwestern Medical Center - SimmonsCompCancerCtr Clinical Research Office - Dallas
  • MD Anderson Cancer Center/University of Texas Thoractic Head/Neck Med. Onc. - Houston

Other

  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Heidelberg

District of Columbia

  • Georgetown University/Lombardi Cancer Center StudyCoordinator:CRAD001C2114 - Washington D.C.

Louisiana

  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center - New Orleans

South Australia

  • Novartis Investigative Site - Adelaide

Victoria

  • Novartis Investigative Site - Heidelberg

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2007-02
Est. Completion 2009-11
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00457119

The ClinicalTrials.gov registry entry for NCT00457119 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which RAD001 is the first listed.

NCT00457119 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Other, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00457119 about?

NCT00457119 is a clinical study titled "Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients". This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy. In step 1 of this study, RAD 001 is given in combination with carboplatin and paclitaxel and in Step 2 RAD001 is given in combination with car...

What is the current status of trial NCT00457119?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2007-02. Estimated completion is 2009-11.

What conditions does trial NCT00457119 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT00457119?

The interventions under investigation include: RAD001 (DRUG).

Who is sponsoring clinical trial NCT00457119?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00457119 being conducted?

This trial has 8 study locations across District of Columbia, Louisiana, Texas, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.